That slide on comparison to other assets was the key one for me. Everything was very positive, particularly confirmation cerebral edema is a very common complication in recurrent GBM.
I got my question in on MMP-2 frequency. Jennifer quoted the known proportion for treatment naive tumours (73%) and said they are evaluating the frequency in recurrent tumours in the trial. It looks as though most tumours will be responsive to CLTX-Car-T.
That slide on comparison to other assets was the key one for me....
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $20.21K | 5.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2213046 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13563373 | 20 |
View Market Depth
| Last trade - 15.01pm 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |